Generation of induced pluripotent stem cells from ADHD patients who do or do not respond to Methylphenidate treatment.
Cristine Marie Yde OhkiNatalie Monet WalterMichelle RickliCedric IseliAnna Maria WerlingChristian DöringBelén RubioPer HoffmannStefan HermsSusanne WalitzaEdna GrünblattPublished in: Stem cell research (2024)
As a neurodevelopmental multifactorial disorder whose prevalence has been increasing worldwide, attention-deficit hyperactivity disorder (ADHD) is considered a public health concern. Methylphenidate (MPH) is the drug of choice for ADHD; however, not all patients respond fully to this treatment. Therefore, exploring the underlying molecular mechanisms involved in ADHD and potential novel therapeutic targets is crucial. Here, we generated induced pluripotent stem cells (iPSCs) from Peripheral Blood Mononuclear Cells (PBMCs) retrieved from four ADHD patients (two MPH responders and two non-responders) using Sendai virus. These lines might be helpful for the in vitro investigation of ADHD pathophysiology in a patient-specific manner.
Keyphrases
- attention deficit hyperactivity disorder
- autism spectrum disorder
- induced pluripotent stem cells
- working memory
- end stage renal disease
- public health
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- peritoneal dialysis
- emergency department
- patient reported outcomes
- combination therapy
- decision making
- adverse drug
- electronic health record